Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor ... detailing the novel mechanism of action and effectiveness of botensilimab, an ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual ...

BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR ... Blocking monoclonal antibody CTLA-4 Phase III Ipilimumab Blocking monoclonal antibody CTLA-4 Phase II MDX-1106 Blocking monoclonal ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

In 2020-2021, a mysterious skin disease affected fishermen in Senegal. High levels of Portimine A toxin, produced by the ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...